Novavax Quick Ratio from 2010 to 2024

NVAX Stock  USD 14.40  0.39  2.64%   
Novavax Quick Ratio yearly trend continues to be fairly stable with very little volatility. Quick Ratio will likely drop to 0.51 in 2024. Quick Ratio is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. View All Fundamentals
 
Quick Ratio  
First Reported
2010-12-31
Previous Quarter
0.53583795
Current Value
0.51
Quarterly Volatility
1.99893898
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 97.33. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
This module can also supplement Novavax's financial leverage analysis and stock options assessment as well as various Novavax Technical models . Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Quick Ratio Growth Pattern

Below is the plot of the Quick Ratio of Novavax over the last few years. It is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. Novavax's Quick Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Quick Ratio10 Years Trend
Slightly volatile
   Quick Ratio   
       Timeline  

Novavax Quick Ratio Regression Statistics

Arithmetic Mean2.82
Geometric Mean2.00
Coefficient Of Variation70.97
Mean Deviation1.51
Median3.02
Standard Deviation2.00
Sample Variance4.00
Range6.9134
R-Value(0.74)
Mean Square Error1.96
R-Squared0.54
Significance0
Slope(0.33)
Total Sum of Squares55.94

Novavax Quick Ratio History

2024 0.51
2023 0.54
2022 0.58
2021 0.82
2020 3.02
2019 3.35
2018 0.48

About Novavax Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novavax income statement, its balance sheet, and the statement of cash flows. Novavax investors use historical funamental indicators, such as Novavax's Quick Ratio, to determine how well the company is positioned to perform in the future. Although Novavax investors may use each financial statement separately, they are all related. The changes in Novavax's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novavax's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novavax Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Quick Ratio 0.54  0.51 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
CEOs Directory
Screen CEOs from public companies around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.05)
Revenue Per Share
8.726
Quarterly Revenue Growth
0.159
Return On Assets
(0.16)
Return On Equity
(8.98)
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.